1. High-Flow Nasal Cannula Therapy for the Management of Hypoxaemic Respiratory Failure in Patients with SARS-CoV-2 Pneumonia: An Observational Cohort Study
- Author
-
Gallardo-Rincón H, Chavarria Ap, Juárez Lm, Wyssmann Rvá, Avendaño Ma, Cerda MLRdl, Gascon Jl, Bello Hh, Benavides Rv, Vazquez Rrv, Castañeda Lm, Lezama Es, Luis Alberto Martinez-Juarez, Navarro Mg, Tapia-Conyer R, Gonzalez Ler, and Ortiz Bs
- Subjects
Mechanical ventilation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Hazard ratio ,medicine.disease_cause ,medicine.disease ,Pneumonia ,Respiratory failure ,Emergency medicine ,medicine ,Observational study ,In patient ,business ,Nasal cannula ,Cohort study - Abstract
Background: The utility of high-flow nasal cannula (HFNC) to reduce the need for invasive mechanical ventilation (IMV) in patients with hypoxaemic respiratory failure due to COVID-19 is poorly understood. Methods: We designed a prospective observational study of a large cohort of patients at the Temporary COVID-19 Hospital (TCH) in Mexico City who had COVID-19-related hypoxaemic respiratory failure. The primary outcome was the success rate of HFNC to prevent the progression to IMV. We also evaluated the risk factors associated with HFNC success or failure. Findings: This study included 378 patients who met the criteria for hypoxaemic respiratory failure and for HFNC use. This study showed that HFNC effectively prevented IMV in 71.4% of patients (n=270; 95% CI: 66·6–75·8). Factors that were significantly different between patients who were only treated with HFNC and those who progressed to IMV included age, the presence of hypertension, and the Charlson comorbidity index. Predictors of HFNC failure included the CALL score at admission (adjusted hazard ratio [HR]: 1·27; 95% CI, 1·09–1·47; p
- Published
- 2021
- Full Text
- View/download PDF